{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T22:52:24Z","timestamp":1777589544338,"version":"3.51.4"},"reference-count":30,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-breast-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.clbc.2024.04.010","type":"journal-article","created":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T15:35:08Z","timestamp":1713886508000},"page":"e545-e553.e6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Cost-effectiveness of Sacituzumab Govitecan versus Single-agent Chemotherapy for Patients with Metastatic Triple-Negative Breast Cancer in China"],"prefix":"10.1016","volume":"24","author":[{"given":"Lei","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lulu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhe","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fushu","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yao","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingbin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyuan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10159","key":"10.1016\/j.clbc.2024.04.010_bib0001","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1016\/S0140-6736(18)32335-3","article-title":"Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"392","year":"2018","journal-title":"Lancet"},{"issue":"25","key":"10.1016\/j.clbc.2024.04.010_bib0002","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.2217\/fon-2018-0131","article-title":"Antibody-drug conjugates in triple negative breast cancer","volume":"14","author":"Tray","year":"2018","journal-title":"Future Oncol"},{"issue":"16","key":"10.1016\/j.clbc.2024.04.010_bib0003","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.clbc.2024.04.010_bib0004","doi-asserted-by":"crossref","first-page":"594","DOI":"10.6004\/jnccn.2023.0031","article-title":"NCCN Guidelines\u00ae Insights: Breast Cancer, Version 4.2023","volume":"21","author":"Gradishar","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"issue":"10","key":"10.1016\/j.clbc.2024.04.010_bib0005","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1007\/s40265-020-01337-5","article-title":"Sacituzumab govitecan: first approval","volume":"80","author":"Syed","year":"2020","journal-title":"Drugs"},{"issue":"10","key":"10.1016\/j.clbc.2024.04.010_bib0006","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1002\/onco.13878","article-title":"Sacituzumab govitecan for metastatic triple-negative breast cancer: clinical overview and management of potential toxicities","volume":"26","author":"Spring","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.clbc.2024.04.010_bib0007","article-title":"Economic evaluation of sacituzumab govitecan for the treatment of metastatic triple-negative breast cancer in china and the US","volume":"11","author":"Chen","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.clbc.2024.04.010_bib0008","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.breast.2023.02.003","article-title":"Cost-effectiveness of sacituzumab govitecan versus chemotherapy in advanced or metastatic triple-negative breast cancer","volume":"68","author":"Lang","year":"2023","journal-title":"Breast"},{"issue":"1","key":"10.1016\/j.clbc.2024.04.010_bib0009","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1186\/s12913-023-09728-6","article-title":"Cost-effectiveness of sacituzumab govitecan versus chemotherapy in patients with relapsed or refractory metastatic triple-negative breast cancer","volume":"23","author":"Xie","year":"2023","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.clbc.2024.04.010_bib0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.vhri.2020.07.580","article-title":"Current development and practice of pharmacoeconomic evaluation guidelines for universal health coverage in China","volume":"24","author":"Yue","year":"2021","journal-title":"Value Health Reg Issues"},{"issue":"2","key":"10.1016\/j.clbc.2024.04.010_bib0011","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.0037","article-title":"Cost-effectiveness of atezolizumab plus bevacizumab vs sorafenib as first-line treatment of unresectable hepatocellular carcinoma","volume":"4","author":"Su","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.clbc.2024.04.010_bib0012","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jval.2021.11.1351","article-title":"Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: updated reporting guidance for health economic evaluations","volume":"25","author":"Husereau","year":"2022","journal-title":"Value Health"},{"key":"10.1016\/j.clbc.2024.04.010_bib0013","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med Res Methodol"},{"issue":"6","key":"10.1016\/j.clbc.2024.04.010_bib0014","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1177\/0272989X12472398","article-title":"Survival analysis for economic evaluations alongside clinical trials\u2013extrapolation with patient-level data: inconsistencies, limitations, and a practical guide","volume":"33","author":"Latimer","year":"2013","journal-title":"Med Decis Making"},{"issue":"2","key":"10.1016\/j.clbc.2024.04.010_bib0015","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s41669-021-00260-z","article-title":"Mixture cure models in oncology: a tutorial and practical guidance","volume":"5","author":"Felizzi","year":"2021","journal-title":"Pharmacoecon Open"},{"issue":"3","key":"10.1016\/j.clbc.2024.04.010_bib0016","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.cmpb.2013.07.021","article-title":"Mixture and non-mixture cure fraction models based on the generalized modified Weibull distribution with an application to gastric cancer data","volume":"112","author":"Martinez","year":"2013","journal-title":"Comput Methods Programs Biomed"},{"key":"10.1016\/j.clbc.2024.04.010_bib0017","unstructured":"National Bureau of Statistics of China (2021). National Bureau of Statistics of China. Available at: http:\/\/data.stats.gov.cn\/english\/index.htm (accessed Sep 30, 2022)."},{"key":"10.1016\/j.clbc.2024.04.010_bib0018","article-title":"Cost-Effectiveness analysis of camrelizumab vs. placebo added to chemotherapy as first-line therapy for advanced or metastatic esophageal squamous cell carcinoma in china","volume":"11","author":"Zhang","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.clbc.2024.04.010_bib0019","unstructured":"Chinese drug (2021). Chinese drug price of drug centralized bid procurement. Available at: https:\/\/db.yaozh.com\/yaopinzhongbiao (accessed Sep 30, 2022)."},{"issue":"9","key":"10.1016\/j.clbc.2024.04.010_bib0020","doi-asserted-by":"crossref","first-page":"3761","DOI":"10.1007\/s12325-020-01418-7","article-title":"Economic evaluation of cisplatin plus gemcitabine versus paclitaxel plus gemcitabine for the treatment of first-line advanced metastatic triple-negative breast cancer in china: using markov model and partitioned survival model","volume":"37","author":"Rui","year":"2020","journal-title":"Adv Ther"},{"issue":"4","key":"10.1016\/j.clbc.2024.04.010_bib0021","doi-asserted-by":"crossref","first-page":"e340","DOI":"10.3747\/co.23.2244","article-title":"Cost-effectiveness of pazopanib compared with sunitinib in metastatic renal cell carcinoma in Canada","volume":"23","author":"Amdahl","year":"2016","journal-title":"Curr Oncol"},{"issue":"1","key":"10.1016\/j.clbc.2024.04.010_bib0022","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1586\/14737167.1.1.37","article-title":"Incremental cost-effectiveness ratio and incremental net-health benefit: two sides of the same coin","volume":"1","author":"Craig","year":"2001","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"2 Suppl","key":"10.1016\/j.clbc.2024.04.010_bib0023","doi-asserted-by":"crossref","first-page":"S68","DOI":"10.1177\/0272989X98018002S09","article-title":"Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis","volume":"18","author":"Stinnett","year":"1998","journal-title":"Med Decis Making"},{"issue":"1","key":"10.1016\/j.clbc.2024.04.010_bib0024","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12939-021-01610-3","article-title":"The burden of household out-of-pocket healthcare expenditures in Ethiopia: a systematic review and meta-analysis","volume":"21","author":"Borde","year":"2022","journal-title":"Int J Equity Health"},{"issue":"1","key":"10.1016\/j.clbc.2024.04.010_bib0025","doi-asserted-by":"crossref","first-page":"93","DOI":"10.21037\/hbsn-2021-3","article-title":"An overview of the Chinese healthcare system","volume":"10","author":"Yi","year":"2021","journal-title":"Hepatobiliary Surg Nutr"},{"issue":"10204","key":"10.1016\/j.clbc.2024.04.010_bib0026","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/S0140-6736(19)32136-1","article-title":"10 years of health-care reform in China: progress and gaps in Universal Health Coverage","volume":"394","author":"Yip","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.clbc.2024.04.010_bib0027","unstructured":"Chinese drug (2022). Chinese drug price of drug centralized bid procurement. Available at: https:\/\/db.yaozh.com\/yaopinzhongbiao (accessed 01 Nov. 2023)."},{"issue":"1","key":"10.1016\/j.clbc.2024.04.010_bib0028","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1186\/s12916-022-02516-9","article-title":"A cost-effectiveness analysis of capecitabine maintenance therapy versus routine follow-up for early-stage triple-negative breast cancer patients after standard treatment from a perspective of Chinese society","volume":"20","author":"Li","year":"2022","journal-title":"BMC Med"},{"key":"10.1016\/j.clbc.2024.04.010_bib0029","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2021.756899","article-title":"Atezolizumab plus chemotherapy vs. chemotherapy in advanced or metastatic triple-negative breast cancer: a cost-effectiveness analysis","volume":"9","author":"Liu","year":"2021","journal-title":"Front Public Health"},{"issue":"5","key":"10.1016\/j.clbc.2024.04.010_bib0030","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1097\/COC.0000000000000671","article-title":"First-line treatment with atezolizumab plus nab-paclitaxel for advanced triple-negative breast cancer: a cost-effectiveness analysis","volume":"43","author":"Weng","year":"2020","journal-title":"Am J Clin Oncol"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820924001101?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820924001101?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T07:49:51Z","timestamp":1726472991000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820924001101"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":30,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S1526820924001101"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2024.04.010","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-effectiveness of Sacituzumab Govitecan versus Single-agent Chemotherapy for Patients with Metastatic Triple-Negative Breast Cancer in China","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2024.04.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}